Sustained Proteinuria Reduction: The 76-Week Pegcetacoplan Data
For patients living with C3 glomerulopathy (C3G), the search for long-term therapeutic stability is often defined by the slow, grinding reality of kidney function decline. New data presented at the American Society of Nephrology Kidney Week 2026 suggests that pegcetacoplan may offer a way to alter this trajectory. According to findings reported by HCPLive, patients treated with the complement inhibitor maintained significant reductions in proteinuria through 76 weeks of exposure.
In the overall study population, the geometric mean change in proteinuria stood at –64.1%, a result that suggests the drug’s biological impact remains consistent well beyond the initial phases of treatment. While the reduction in protein leakage is a primary clinical marker, the true “so what” for patients and clinicians lies in what happens to the estimated glomerular filtration rate (eGFR). The data showed an annualized eGFR slope of –1.4 mL/min/1.73 m² per year, indicating a stabilization that contrasts with the typical, more aggressive decline often seen in the natural history of the disease.
The Influence of Baseline Kidney Scarring
The effectiveness of the therapy appears to be tied closely to the state of the kidney at the time treatment begins. Investigators categorized participants by their baseline interstitial fibrosis and tubular atrophy (IFTA)—a measure of how much permanent scarring is already present in the kidney tissue.
The divergence in outcomes between these subgroups is stark:
| Baseline IFTA | Proteinuria Change | LS Mean eGFR Change |
|---|---|---|
| ≤25% | –66.8% | +1.7 mL/min/1.73 m² |
| 26% to 50% | –52.6% | –11.0 mL/min/1.73 m² |
For those with minimal scarring (IFTA ≤25%), the treatment not only reduced proteinuria by nearly 67% but was associated with a modest increase in eGFR. Conversely, patients who entered the study with more significant fibrosis (26% to 50%) saw a sharper decline in kidney function, losing an average of 11.0 mL/min/1.73 m² despite the treatment.
Carla Nester, MD, who discussed the findings, pointed to these numbers as a clear signal for clinical practice.
“For the average clinician, what that should mean, for me certainly it did, is that treating early is key,” Nester said. “So using targeted therapy early feels to me, you know, by this data to be the right thing to do.”
Mandatory Vaccinations Mitigate Serious Infection Risks from Pegcetacoplan
While the efficacy data provides a compelling case for early intervention, the clinical reality of complement inhibition remains tethered to significant safety requirements. Pegcetacoplan carries an FDA boxed warning regarding the risk of serious infections caused by encapsulated bacteria. This is not a theoretical concern; it is a clinical mandate that requires rigorous adherence to vaccination schedules before a patient ever receives their first dose.
The 76-week interim analysis reported no new, unexpected safety signals, with common adverse events limited to issues like headaches and cough. However, as noted in the official prescribing information, the absence of new signals in this specific cohort does not negate the underlying, life-threatening risks associated with long-term complement blockade. Clinicians must balance the potential for long-term kidney preservation against the immediate, documented need for infection-risk mitigation.
The Path Toward Standardized Care
The medical community is still working to determine exactly where this therapy fits into the broader management of C3G. As Nester noted, while the extension analysis is encouraging, it was not a randomized, head-to-head comparison against an untreated control group. This leaves open questions about how much of the observed stabilization is directly attributable to the drug versus the background standard of care, which includes blood pressure and lipid management.
Looking ahead, the integration of complement inhibitors into routine care will likely depend on the development of formal treatment guidelines and the accumulation of real-world epidemiologic data. There is also the question of whether this therapy can eventually replace more traditional, broader immunosuppressive agents. For now, the focus remains on the window of opportunity—the realization that once significant fibrosis has taken hold, the ability of targeted therapy to reverse or even halt damage appears to diminish.
The data confirms that pegcetacoplan is effective at lowering proteinuria, but the clinical challenge remains in identifying and treating patients early enough to capitalize on that protection before the kidney tissue is permanently altered.
